SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatment algorithm in axPsA (as the predominant domain?) Poster #POS1045 #EULAR2021 @RheumNow
EULAR 2021 Tweet by Dr. Rachel Tate
TweetRelated Content
Podcast
DERM on RheumNow PODCAST (September 2026)
RheumNow
Sep 30, 2026
The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors.
Features Dr. Jack Cush, Editor at RheumNow.com.
Show Notes:
FDA Grants Priority…
What's New in Spondyloarthritis
Robert Chao, MD
Feb 17, 2026
Dr. Arthur Kavanaugh and Dr. Eric Ruderman gave an update on what's new in spondyloarthritis at the 2026 Rheumatology Winter Clinical Symposium (RWCS) in Maui, Hawaii. Here's a summary.
2026 Guidelines for the Treatment of Axial Spondyloarthritis
ACR
Jun 25, 2026
New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children. The effort includes an update to the 2019 ACR/SAA/SPARTAN treatment guidelines focusing on adults, alongside a…
